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We have previously shown that unsaturated phosphatidylserines inhibit mitogen-induced T cell activation. We now report that the inhibitory action 
requires a protein present in bovine and human serum. Partial purification and phospholipase assay show that this protein has phospholipase A 
activity on phosphatidylserine but not phosphatidylethanolamine, phosphatidylcholine and phosphatidylinositol. In short incubations (l-3 h) 2-acyl 
lysophosphatidylserine is produced but in longer incubations the c&unsaturated fatty acid is also released. Experiments on peripheral blood 
mononuclear cells indicate that the unsaturated fatty acid becomes the main responsible for the PS-induced inhibition and that 2-acyl lysophosphat- 
idylserine enhances the inhibitory effect of fatty acid. 
Phospholipase A,; Phosphatidyls~rine~ Lysophosphatidylserine (Z-acyl); T cell activation; Fetal calf serum 
1. INTRODUCTION 
The anionic phospholipid phosphatidylserine (PS) in- 
hibits mitogen-induced T cell activation [1,2]. Lympho- 
cyte inhibition is also observed with other lipid com- 
pounds (e.g. cholesterol) and with lipoproteins [3,4]. 
Based on the antagonism by transferrin, it has been 
proposed that cholesterol and lipoproteins affect trans- 
ferrin metabolism [3]. Since it is not known whether a 
direct or mediated mechanism is involved in PS-induced 
inhibition we have examined the action of this phospho- 
lipid on peripheral blood mononuclear cells (PBMC) in 
serum-free and serum-containing medium. The data 
show that the action of PS requires a serum factor with 
phospholipase activity toward this phospholipid. 
porcine pancreas phospholipase A, (Boehringer), fetal calf serum 
(FCS, Seromed); phenyl-Sepharose CL4B and heparin-Sepharose 
CL6B (Pharmacia). 
PBMC from heparinized human blood (10’ cells/well containing 0.2 
ml of RPM1 medium) were cultured 72 h at 37°C in humidified air 
~ontainin8 5% COz [I]. Phytohemagglutinin (PHA) was used at 1 
&ml. To evaluate DNA synthesis the cells were pulsed with 1 pCi of 
[‘Hjthymidine @H]dThd) during the last 18 h of cultures. 
2.3. Assay of phosphoiipase activity 
2. MATERIALS AND METHODS 
2.1, Phospholipids and other materials 
PS was obtained from bovine brain and purified on Q Sepharose. 
Purity was assessed by thin layer chromatography. Oleic acid (34%) 
and stearic acid (49%) were the predominant fatty acids. 2-acyl lysoPS 
was prepared by the digestion of PS with adult bovine serum (2 ml/mg 
of PS, 3 h at 37’(Z), followed by differential solvent extraction [S]. To 
prepare [~H]ara~hidonoyl-PS, 10’ PBMC were incubated 30 min at 
37°C with 50 @Zi of t3~]arachidonate and 5 @vi of l-acyl IysoPS 
which was obtained from PS as described previously [6]. Phospholip- 
ids were then extracted with chlorofo~methallo~ (t:l, v/v) and PS 
purified by thin layer chromatography. Digestion with phospholipase 
A, from porcine pancreas showed that the tracer was exclusively 
incorporated in position 2 of glycerol. Other radiolabeled lipids were 
from Amersham. Transferrin, prostacyclin and fatty acid-free bovine 
serum albumin (BSA) were from Sigma; heparin (Liquemin Roche); 
The fractions obtained in the procedure developed to partially pu- 
rify the serum factor enhancing the action of PS (see Results and 
Discussion) were tested for phospholipase activity in 0.2 ml of phos- 
phate saline buffer (pH 7.4) containing 0.5 mM of Ca” and a soni- 
cated dispersion of radiolabeled phospholipids (6 nmol, 3-6 x 10J 
dpm/nmol). FCS was added at 1 and 10% (v/v) corresponding to 80 
and 800 pug protein/ sample. Purified fractions were added at 5 pcgi 
sample together with lOOfig of BSA. The incubation was 3 h at 37°C. 
The activity was Cd”- dependent (0.2-0.5 mM) and constant between 
pH 7.4 and 9. The reaction was stopped with 2.0 ~01s. of chloroform 
methanol (2: I, v/v) and the lipid extract, washed with 0.2 ~01s. of 0.05 
M HCl, was resolved by thin layer chromatography. 
3. RESULTS AND DISCUSSION 
Correspondence address: A. Bruni, Dept. of Pharmacology, University 
of Padova, Largo Meneghetti 2, 35131 Padova, Italy. Fax: (39) (49) 
831878. 
When compared to medium containing FCS, PHA- 
induced DNA synthesis in serum-free cultures was di- 
minished but still detectable 171. Transferrin substan- 
tially increased [3H]dThd incorporation (81. Under these 
conditions PS partially inhibited DNA synthesis in the 
absence of transferrin (mean value of 44% at 30pM) but 
was ineffective in its presence (Fig. 1). In serum-contain- 
ing medium transferrin still increased DNA synthesis [8] 
but did not affect the PS inhibitory effect (IC,, at 1.5 ,uM 
with and without transferrin), Similar results were ob- 
tained with increasing transferrin concentrations (up to 
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Fig. 1. Effect of fetal calf serum on the PS-induced inhibition. 
lo5 PBMC were cultured in the presence of 1 ,&ml of PHA in 0.2 ml 
of RPM1 medium. Additions: (0) 1 mg/ml of BSA; (e) BSA plus 50 
&ml of transferrin; (a) 5% (v/v) of fetal calf serum; (A) fetal calf 
serum plus transferrin. Means + S.E.M. for 15 experiments, each in 
triplicate and with different donors. Without PHA [‘HjdThd uptake 
was 0.8-2.0 cpm x lo-‘. 
200 ,&ml) or supplementing the medium with adult 
bovine or human serum (not shown). From these data 
we concluded that although transferrin influenced a 
minor component of PS action becoming manifest in 
serum-free medium, its effect was not sufficient to over- 
come the action of PS when enhanced by serum. In this 
respect, PS was unlike lipoproteins and cholesterol [S]. 
The factor enhancing the action of PS was recovered in 
lipoprotein-free serum (density of 1.21 g/ml) from where 
it could be precipitated by ammonium sulfate at 60% 
saturation. Partial purification was facilitated when it 
was found that the protein had phospholipase A activity 
on PS. Undialyzed lipoprotein-free FCS was applied at 
4°C to a column of phenyl-Sepharose (Fig. 2A). The 
water-eluted fraction (fraction 3) was incubated over- 
night at 4°C with heparin-Sepharose in 50 mM NaCl, 
10 mM Tris, 1 mM EDTA (pH 7.4). After pouring in 
a column, proteins were eluted (Fig. 2B). Unretained 
proteins showed negligible phospholipase activity which 
was instead concentrated in fraction 5. SDS-PAGE 
under reducing conditions showed that fraction 5 had 
TIME (h) 
Fig. 2. Step-wise lution of serum factor in phenyl-Sepharose (A) and 
heparin-Sepharose (B) columns. The continuous recording of column 
efflux (1 ml/min) shows the elution of serum proteins in A and of 
proteins from fraction 3 in B. The activity was found in fractions 3 and 
5 which were stored at -20°C in Tris, NaCl buffer containing 30% 
glycerol (v/v) after concentration with solid ammonium sulfate (frac- 
tion 3) and washing on C25 Amicon Cones. 
two main bands of 60 and 120 kDa and several minor 
bands when visualized by silver staining. Phospholipase 
activity (nmol lysoPS/mg/3 h) provided preliminary in- 
dications of purification and activity yield. The specific 
activity of FCS (6.3 ? 3.5, mean rt S.D., n = 4) increased 
to 180 & 34 in fraction 3 and to 2 15 & 30 in fraction 5. 
The yield of proteins was 3.7 rt 1.1% of serum protein 
in fraction 3 and about 0.4% in fraction 5. These data 
indicated good yield of activity in phenyl-Sepharose but 
loss in heparin-Sepharose. Although the reason for the 
activity loss needs to be investigated, the property of the 
enzyme to be bound to heparin-Sepharose was consid- 
ered of interest since hydrophobic interaction with 
phenyl-Sepharose and binding to heparin-Sepharose 
were previously observed with lipid transfer proteins [9] 
and lipoprotein lipase [lo]. The fractions enhancing the 
action of PS on PBMC had the highest phospholipase 
activity suggesting that the two activities were related 
(Table If. Kinetic experiments (Fig. 3) established that 
in 1-3 h of incubation phospholipase activity was pri- 
marily of the A, type generating 2-acyl lysoPS. In longer 
incubations also 2-acyl 1ysoPS was hydrolyzed with re- 
lease of unsaturated fatty acids and glycero-P-serine 
(which was detected with [‘4C]serine-PS). Explanations 
include the possibility that phospholipase A, had some 
activity on position 2 of glycerol [l l] or that unsaturated 
fatty acid migrated to the sn-1 position in long incuba- 
tions. In accord with a single enzyme releasing and 
splitting 2-acyl lysoPS, the two activities showed the 
same optimal pH and Ca*+ requirement and were simi- 
larly enriched during partial purification. Among PS 
2 
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metabolites (Table II) the cis-unsaturated fatty acid 
(oleate) rather than stearate was the effective inhibitor 
of PHA-activated PBMC cultured in serum-free me- 
dium. 2-acyl lysoPS increased DNA synthesis but en- 
hanced oleate-induced inhibition. Purified phospholip- 
ase A 2 releasing unsaturated fatty acids from PS, par- 
tially reproduced the action of serum factor in the ab- 
sence of 2-acyl lysoPS but was fully effective in its pres- 
ence. Since these results were the same in the presence 
and absence of transferrin (not shown) it was concluded 
that the inhibition by oleate and PS plus phospholipase 
A2 was not mediated by interference with the action of 
transferrin. 
Phospholipase activity on PS was detected in serum 
of several mammals (Fig. 4). However, only bovine and 
human serum showed preference for PS. Activity was 
also found in heparinized plasma obtained in the pres- 
ence of prostacyclin to avoid platelet activation. Since 
inhibition by heparin [12] was not observed, the lower 
activity of plasma was interpreted as phospholipase ac- 
tivation during blood clotting. Unlike lipoprotein lipase 
and hepatic lipase [10,13], the enzyme from bovine and 
human serum did not hydrolyze PE and PC in a pH 
range between 7 and 10 and after the addition of de- 
oxycholate or diethylether (not shown). Generation of 
lysoPI from phosphatidylinositol as well as lipase activ- 
ity toward [3H]triolein were not detected. Heating 30 
min at 56°C partially inactivated FCS and completely 
inhibited fraction 5. 
In conclusion, we have shown that bovine and human 
serum contains a phospholipase A~ which preferentially 
cleaves PS in comparison to PC, PE and PI. The enzyme 
Table I 
Relationship between the enhancing effect of fetal calf serum (FCS) 
and its phospholipase activity 
Exp. Additions [~H]dThd incorporation ~ Phospho- 
lipase 
Without PS 30,uM PS activity b
1. 1 mg/ml BSA 37.2 ± 3.5 43.1 +- 4,1 
1% (v/v) FCS 47.9 _+ 0.7 0,9 +_ 0.2 (98%) 11.5 
BSA plus 
fraction 1 c 29.5 +- 2.6 41.8 +- 4,4 1.3 
BSA plus 
fraction 2 27.5 +- 2.2 43.6 +- 10.9 1.4 
BSA plus 
fraction 3 24,3 + 3.5 4.6 +- 03 (81%) 138 
2. 1 mg/ml BSA 23.l +- 1.1 38.8 ± 0.4 
BSA plus 
fraction 4 25.2 ± 1.5 37.4 ± 5.9 7.6 
BSA plus 
fraction 5 30.1 + 1.1 8.8 +- 0.2 (71%) 195 
10 ~ PBMC activated by 1/lg/ml of PHA were cultured in serum-free 
medium in the presence of 50 ¢tg/ml of transferrin, cpm/culture 
(x 10 ~3). Mean + S.D. of triplicate samples. 
blysoPS generation (nmoltmg of protein in 3 h of incubation). 
50/~g/ml of fractions 1 3 (from phenyl-Sepharose); 10 ktg/ml of frac- 
tions 4,5 (from heparin-Sepharose). 
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Fig. 3. Phospholipase activity with 2-[3H]arachidonoyl-PS. 6 nmol of 
PS (24,000 dpm) were incubated with 5,ug of fraction 5 from heparin- 
Sepharose. (o) PS; (e) lysoPS; (z~) free arachidonate. 
generates 2-acyl lysoPS which in long incubations i
further hydrolyzed releasing its cis-unsaturated fatty 
acid. These metabolites become then the main responsi- 
ble for PS-induced T cell inhibition. In agreement, only 
PS containing unsaturated acyl chains prevents T cell 
activation [1,2] and previous observations confirm the 
Table II 
Action of PS metabolites and pancreas phospholipase A 2 (PLA2) 
Exp, 
1. 
2. 
Additions [3H]dThd incorporation 
(cpm/culture x 10 -3) 
Minus lysoPS Plus 2-acyl lysoPS 
None 53.2 _+ 10.5 69.1 +- 6.2 
5 yM oleate 21.0 +- 12.2 (60%) 5.4 + 7.4 (92%) 
10 pM stearate 79.0 +- 12.2 54.3 +_ 10.8 (21%) 
None 33.6 -+ 1.9 58.8 _+ 4.0 
20 ng PLA 2 53.4 + 1.6 65.0 _+ 1.8 
30/~M PS 68.1 +_2.2 53,7_ + 1.2 
PS plus PLA 2 35.2 +- 5.3 (48%y' 0.8 + 0.4 (98%) ~ 
105 PBMC were cultured in the presence of 1/tg/ml PHA, 50 pg/ml 
transferrin in 0.2 ml RPMI supplemented with 1 mg/ml BSA. 10 ,uM 
2-acyl lysoPS. Mean + S.D. of 6 (exp. 1) or 3 (exp. 2) cultures. In 
parentheses the percent inhibition. 
with respect o PS alone. 
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Fig. 4. Phospholipase A activity in sera or plasma (hatched bars) from 
mammals. 6 nmol of [r4CJserine-PS, phosphatidyl-[‘4C]ethanolamine 
(PE), 2-[‘4C]oleoylphosphatidylcholine (PC) incubated 3 h at 37°C in 
0.2 ml of phosphate saline buffer (pH 7.4) with 10% (v/v) of serum 
(l-1.4 mg of protein) or plasma obtained in the presence of 20 IUlml 
of heparin and 1 PM of prostacyclin. Means -t S.D. of at least 7 
donors. Tests with 2-[~H]arachidonoyl-PS gave the following IysoPSl 
free arachidonate ratio (A,/AZ ratio): mouse, 1.8; rat, 3.0; rabbit, 3.1; 
bovine, 28.3; man, 28.5. 
inhibitory effect of oleate on these cells 17,145 The de- 
tection of serum phospholipase A, lends support to our 
hypothesis that hydrolysis of PS in damaged tissues 
yields metabolites acting on immune cells [1.5]. Phos- 
pholipase A, acting on PS have been detected in rat liver 
membranes [ 161 and rat liver lysosomes [ 171. 
Aeknu~ledgemenf~: We are indebted to Dr. C. Chizzolini for criticism 
and advice. 
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